2 terminated, 2 withdrawn, 1 completed. 4 Phase 2, 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 2, Withdrawn 2 |
| Phase 1 | 2 | Terminated 2 |
| Early Phase 1 | 1 | Completed 1 |
Follow orilanolimab: new trials by email Literature Review of orilanolimab trials Research Report on orilanolimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia ALXN1830, Placebo - Warm Autoimmune Hemolytic Anemia | Phase 2 | Withdrawn | Alexion Pharmaceuticals, Inc. | 2022-01-01 | 2022-02-11 | |
| ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia ALXN1830, Placebo - Warm Autoimmune Hemolytic Anemia | Phase 2 | Withdrawn | Alexion Pharmaceuticals, Inc. | 2021-07-01 | 2020-07-13 | |
| A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) ALXN1830 - Warm Autoimmune Hemolytic Anemia | Phase 1 / Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 8 | 2018-01-10 | 2020-05-13 |
| A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) ALXN1830 - Pemphigus, Pemphigus Vulgaris | Phase 1 / Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 8 | 2017-07-18 | 2020-02-05 |
| A Study of SYNT001 in Healthy Volunteers SYNT001, Placebo - Healthy | Early Phase 1 | Completed | Syntimmune, Inc. | 31 | 2016-08-17 | 2018-08-24 |
Pemphigus (1)
Alexion Pharmaceuticals, Inc. (4) · Syntimmune, Inc. (1)
United States (5) · Jordan (1)